1. P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM). (23rd June 2022) Authors: Sperling, A. S.; Nikiforow, S.; Derman, B.; Nadeem, O.; Mo, C.; Laubach, J.; Anderson, K.; Alonso, A.; Im, S.-Y.; Ikwgawa, S.; Prabhala, R.; Hernandez Rodriduez, D.; Daley, H.; Shaw, K. L.; Arihara, Y.; Ansari, S.; Quinn, D. S.; Pearson, D.; Hack, A.; Treanor, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MO-0060 prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer. (May 2022) Authors: Hack, A.; Zweemer, R.P.; Jonges, T.N.; Van der Leij, F.; Gerestein, C.G.; Peters, M.; Jürgenliemk-Schulz, I.M.; Van Rossum, P.S. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗